Certolizumab treatment during late pregnancy in patients with rheumatic diseases: Low drug levels in cord blood but possible risk for maternal infections. A case series of 13 patients

Joint Bone Spine

Volumn 83, Issue 3, 2016, Pages 341-343

  Förger, Frauke ^a   Zbinden, Astrid ^a   Villiger, Peter M ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Certolizumab; Pregnancy; Rheumatoid arthritis; Spondyloarthritis

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; FC RECEPTOR; HYDROXYCHLOROQUINE; INFLIXIMAB; PREDNISONE; SALAZOSULFAPYRIDINE; ANTIRHEUMATIC AGENT;

ARTICLE; BIRTH WEIGHT; BREAST FEEDING; BREAST MILK; CLINICAL ARTICLE; DISEASE ACTIVITY; DISEASE CONTROL; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; FEMALE; GESTATIONAL AGE; HUMAN; INFECTION RISK; LOW DRUG DOSE; MATERNAL BLOOD; MATERNAL DISEASE; MATERNAL PLASMA; PLACENTAL TRANSFER; PREGNANCY OUTCOME; PUERPERIUM; PYELONEPHRITIS; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SEPTICEMIA; SHARED DECISION MAKING; SPONDYLARTHRITIS; THIRD TRIMESTER PREGNANCY; UMBILICAL CORD BLOOD; ARTHRITIS, RHEUMATOID; CHEMICALLY INDUCED; CHEMISTRY; FETUS BLOOD; NEWBORN; PREGNANCY; PREGNANCY COMPLICATION; PREMATURITY; RISK ASSESSMENT; RISK FACTOR;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CERTOLIZUMAB PEGOL; FEMALE; FETAL BLOOD; HUMANS; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREMATURE BIRTH; RISK ASSESSMENT; RISK FACTORS; SPONDYLARTHRITIS;

EID: 84947968411     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2015.07.004     Document Type: Article

References (13)

1. de Man, Y.A., Dolhain, R.J., van de Geijn, F.E., et al. Disease activity of rheumatoid arthritis during pregnancy: results from a nationwide prospective study. Arthritis Rheum 59 (2008), 1241–1248.
2. Ostensen, M., Husby, G., A prospective clinical study of the effect of pregnancy on rheumatoid arthritis and ankylosing spondylitis. Arthritis Rheum 26 (1983), 1155–1159.
3. Forger, F., Vallbracht, I., Helmke, K., et al. Pregnancy mediated improvement of rheumatoid arthritis. Swiss Med Wkly, 142, 2012, w13644.
4. de Man, Y.A., Hazes, J.M., van der Heide, H., et al. Association of higher rheumatoid arthritis disease activity during pregnancy with lower birth weight: results of a national prospective study. Arthritis Rheum 60 (2009), 3196–3206.
5. Marchioni, R.M., Lichtenstein, G.R., Tumor necrosis factor-alpha inhibitor therapy and fetal risk: a systematic literature review. World J Gastroenterol 19 (2013), 2591–2602.
6. Cheent, K., Nolan, J., Shariq, S., et al. Fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease. J Crohn's Colitis 4 (2010), 603–605.
7. Mahadevan, U., Wolf, D.C., Dubinsky, M., et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 11 (2013), 286–292 [quiz e24].
8. Ostensen, M., Forger, F., How safe are anti-rheumatic drugs during pregnancy?. Curr Opin Pharmacol 13 (2013), 470–475.
9. Ostensen, M., Fuhrer, L., Mathieu, R., et al. A prospective study of pregnant patients with rheumatoid arthritis and ankylosing spondylitis using validated clinical instruments. Ann Rheum Dis 63 (2004), 1212–1217.
10. Wallenius, M., Skomsvoll, J.F., Irgens, L.M., et al. Pregnancy and delivery in women with chronic inflammatory arthritides with a specific focus on first birth. Arthritis Rheum 63 (2011), 1534–1542.
11. Michaud, T.L., Rho, Y.H., Shamliyan, T., et al. The comparative safety of tumor necrosis factor inhibitors in rheumatoid arthritis: a meta-analysis update of 44 trials. Am J Med 127 (2014), 1208–1232.
12. Greenberg, J.D., Reed, G., Kremer, J.M., et al. Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis 69 (2010), 380–386.
13. Cunnington, M., Kortsalioudaki, C., Heath, P., Genitourinary pathogens and pre-term birth. Curr Opin Infect Dis 26 (2013), 219–230.